| Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study DA Hughes, K Nicholls, SP Shankar, G Sunder-Plassmann, D Koeller, ... Journal of medical genetics 54 (4), 288-296, 2017 | 430 | 2017 |
| Safety and pharmacodynamic effects of a pharmacological chaperone on α-galactosidase A activity and globotriaosylceramide clearance in Fabry disease: report from two phase 2 … DP Germain, R Giugliani, DA Hughes, A Mehta, K Nicholls, L Barisoni, ... Orphanet journal of rare diseases 7, 1-11, 2012 | 166 | 2012 |
| Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised … D Jones, PF Boudes, MG Swain, CL Bowlus, MR Galambos, BR Bacon, ... The lancet Gastroenterology & hepatology 2 (10), 716-726, 2017 | 163 | 2017 |
| A phase 2 study of migalastat hydrochloride in females with Fabry disease: selection of population, safety and pharmacodynamic effects R Giugliani, S Waldek, DP Germain, K Nicholls, DG Bichet, JK Simosky, ... Molecular Genetics and Metabolism 109 (1), 86-92, 2013 | 127 | 2013 |
| Drug compliance in therapeutic trials: a review P Boudes Controlled clinical trials 19 (3), 257-268, 1998 | 112 | 1998 |
| A pharmacogenetic approach to identify mutant forms of α‐galactosidase a that respond to a pharmacological chaperone for Fabry disease X Wu, E Katz, MCD Valle, K Mascioli, JJ Flanagan, JP Castelli, ... Human mutation 32 (8), 965-977, 2011 | 96 | 2011 |
| A randomized, double‐blind, active‐and placebo‐controlled efficacy and safety study of arhalofenate for reducing flare in patients with gout J Poiley, AS Steinberg, YJ Choi, CS Davis, RL Martin, CA McWherter, ... Arthritis & Rheumatology 68 (8), 2027-2034, 2016 | 80 | 2016 |
| Oral migalastat HCl leads to greater systemic exposure and tissue levels of active α-galactosidase A in Fabry patients when co-administered with infused agalsidase DG Warnock, DG Bichet, M Holida, O Goker-Alpan, K Nicholls, M Thomas, ... PLoS One 10 (8), e0134341, 2015 | 76 | 2015 |
| The challenges of new drugs benefits and risks analysis: lessons from the ximelagatran FDA Cardiovascular Advisory Committee PF Boudes Contemporary clinical trials 27 (5), 432-440, 2006 | 62 | 2006 |
| Migalastat HCl Reduces Globotriaosylsphingosine (Lyso-Gb3) in Fabry Transgenic Mice and in the Plasma of Fabry Patients B Young-Gqamana, N Brignol, HH Chang, R Khanna, R Soska, M Fuller, ... PLoS One 8 (3), e57631, 2013 | 55 | 2013 |
| An open‐label study to determine the pharmacokinetics and safety of migalastat HCl in subjects with impaired renal function and healthy subjects with normal renal function FK Johnson, PN Mudd Jr, T DiMino, J Vosk, S Sitaraman, P Boudes, ... Clinical Pharmacology in Drug Development 4 (4), 256-261, 2015 | 54 | 2015 |
| Duvoglustat HCl increases systemic and tissue exposure of active acid α-glucosidase in Pompe patients co-administered with alglucosidase α P Kishnani, M Tarnopolsky, M Roberts, K Sivakumar, M Dasouki, ... Molecular Therapy 25 (5), 1199-1208, 2017 | 52 | 2017 |
| The pharmacodynamics, pharmacokinetics, and safety of arhalofenate in combination with febuxostat when treating hyperuricemia associated with gout AS Steinberg, BD Vince, YJ Choi, RL Martin, CA McWherter, PF Boudes The Journal of rheumatology 44 (3), 374-379, 2017 | 44 | 2017 |
| A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis CL Bowlus, MR Galambos, RJ Aspinall, GM Hirschfield, DEJ Jones, ... Journal of hepatology 77 (2), 353-364, 2022 | 42 | 2022 |
| Pharmacokinetics and safety of migalastat HCl and effects on agalsidase activity in healthy volunteers FK Johnson, PN Mudd Jr, A Bragat, M Adera, P Boudes Clinical Pharmacology in Drug Development 2 (2), 120-132, 2013 | 42 | 2013 |
| Gene therapy as a new treatment option for inherited monogenic diseases PF Boudes European journal of internal medicine 25 (1), 31-36, 2014 | 40 | 2014 |
| TSE-424, a novel tissue selective estrogen, reduces biochemical indices of bone metabolism in a dose related fashion. S Ronkin, L Clarke, P Boudes, G Constantine JOURNAL OF BONE AND MINERAL RESEARCH 16, S413-S413, 2001 | 36 | 2001 |
| Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study GM Hirschfield, ML Shiffman, A Gulamhusein, KV Kowdley, JM Vierling, ... Hepatology 78 (2), 397-415, 2023 | 26 | 2023 |
| Novel quantitative method to evaluate globotriaosylceramide inclusions in renal peritubular capillaries by virtual microscopy in patients with fabry disease L Barisoni, JC Jennette, R Colvin, S Sitaraman, A Bragat, J Castelli, ... Archives of pathology & laboratory medicine 136 (7), 816-824, 2012 | 26 | 2012 |
| A randomized controlled trial of a protease inhibitor (saquinavir) in combination with zidovudine in previously untreated patients with advanced HIV infection. S Vella, A Lazzarin, G Carosi, A Sinicco, O Armignacco, G Angarano, ... Antiviral therapy 1 (3), 129-140, 1996 | 26 | 1996 |
